From 2009 to 2014, a Spanish harm reduction service analyzed over 17,000 drug samples and found the new psychoactive tryptamines 4-HO-DiPT and 4-AcO-DiPT in 16 samples each, and DiPT in only 4. Nine samples contained both 4-HO-DiPT and 4-AcO-DiPT. Deliveries of 4-HO-DiPT increased over the study period (4 samples in 2014), while those of 4-AcO-DiPT and DiPT decreased (1 sample each in 2014). This trend suggests a progressive replacement of 4-AcO-DiPT and DiPT by 4-HO-DiPT for recreational use. Clinical concern arises from the growing use and lack of scientific evidence on humans, with effects predicted only from users' subjective experiences.
A 31-year-old male military veteran with moderate alcohol use disorder received sequential treatment with ibogaine hydrochloride (1550 mg, 17.9 mg/kg) followed by vaporized 5-MeO-DMT (bufotoxin source 50 mg, estimated 5-MeO-DMT content 5–7 mg) at an inpatient clinic in Mexico. SPECT neuroimaging before and 3 days after the program showed increased brain perfusion in bilateral caudate nuclei, left putamen, right insula, and temporal, occipital, and cerebellar regions. The patient reported improved mood, cessation of alcohol use, and reduced cravings at 5 days, sustained at 1 month, with a partial return to mild alcohol use at 2 months. The findings suggest short-term therapeutic outcomes and warrant further investigation.